HENDERSON, Nev.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCBB:RBCC) joint venture partner Nano3D Biosciences (n3D) has signed a major worldwide distribution agreement with Reprocell for its revolutionary three-dimensional bioprinting product lines. Under the pact, Reprocell will market and sell n3D’s BioAssembler and Magnetic 3D Bioprinting products to academic and governmental-institute life science researchers as well as to the pharmaceutical and biotech industries.
“This red-letter global distribution agreement will provide researchers much easier access to our cutting-edge 3D cell culture system,” said n3D President and Chief Science Officer Glauco Souza. “Reprocell has very strong networks in academia and on the industrial side, too, both in North America, Asia and the European Union. With the BioAssembler and Magnetic 3D Bioprinting product lines available now to a wider array of researchers, we can expect to see faster advances in life sciences, drug discovery and personalized medicine.”
RBCC CEO Kimberly Palmer added, “3D bioprinting has tremendous potential for good in so many key areas now under research. We’re quite happy these important product lines will now be available for academic and industrial use worldwide. This milestone agreement will not only build shareholder value, it will also provide life science researchers valuable tools to improve treatments for many diseases, such as cancer.”
The agreement successfully culminates RBCC’s and n3D’s recent efforts to boost awareness of their 3D bioprinting capabilities. The BioAssembler and Magnetic 3D devices use biocompatible magnetic nanoparticles to magnetically bioprint and levitate cells, allowing them to grow into 3D structures much faster and more simply than competing technologies.
For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.